Adroit revitalizes legacy therapies by reformulating or advancing them through the 505(b)(2) regulatory pathway, ensuring each product aligns with modern standards of safety, efficacy, and patient convenience. Through these methods, we improve established drug formulations and make treatments more accessible to patients who may otherwise face limited options. Our current portfolio emphasizes Respiratory and Pain Management therapies, while we continue to explore additional therapeutic areas to broaden our impact and address unmet medical needs.
Our reformulated oral syrup targets many of the symptoms associated with allergies and the common cold in adults, addressing the growing demand for upper respiratory medications. Designed for convenience, safety, and effectiveness, it meets global patient needs.
Developed using the 505(b)(2) pathway, this pain management product is specifically designed for elderly patients and those with swallowing difficulties, addressing significant unmet medical needs.
